LAVA Therapeutics (LVTX) Projected to Post Earnings on Wednesday

LAVA Therapeutics (NASDAQ:LVTX) is anticipated to post its quarterly earnings results before the market opens on Wednesday, March 19th. Analysts expect LAVA Therapeutics to post earnings of ($0.32) per share and revenue of $2.40 million for the quarter.

LAVA Therapeutics Price Performance

NASDAQ:LVTX opened at $1.30 on Monday. LAVA Therapeutics has a 12-month low of $0.85 and a 12-month high of $4.21. The firm has a market capitalization of $34.19 million, a P/E ratio of -1.26 and a beta of 0.48. The business has a 50 day simple moving average of $1.07 and a 200 day simple moving average of $1.39.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Leerink Partnrs lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Citizens Jmp lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. JMP Securities reiterated a “market perform” rating and set a $6.00 price target on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Leerink Partners reiterated a “market perform” rating and set a $2.00 price target (down previously from $11.00) on shares of LAVA Therapeutics in a research report on Thursday, December 12th. Finally, HC Wainwright reiterated a “neutral” rating and set a $1.50 price target (down previously from $2.00) on shares of LAVA Therapeutics in a research report on Thursday, February 27th. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $3.17.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.